A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy
PLOS One · 2025
DOI: 10.1371/journal.pone.0328305 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Ibrahim H Eissa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Thiadiazoles, ErbB Receptors, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University.
Abstract (Originalsprache)
A novel sulfamoylphenyl-dihydro-thiadiazole derivative (compound 14 ) has been designed and synthesized as a dual inhibitor targeting EGFR and human carbonic anhydrases (hCA_IX and hCA_XII). Computational studies, including density functional theory (DFT), molecular docking, and molecular dynamics simulations, confirmed its stability, favorable binding interactions, and reactivity profiles. Compound 14 showed potent inhibition of EGFR (IC₅₀ = 10.12 ± 0.29 nM), hCA_IX and hCA_XII (IC₅₀ = 79 ± 1.2 nM and 58 ± 0.9 nM, respectively). Cytotoxicity assays demonstrated selective activity against cancer cells, with IC₅₀ values of 16.13 µM in MDA-MB-231 and 22.57 µM in MCF-7 cells, compared to 148.32 µM in non-cancerous Vero cells. Compared to acetazolamide, compound 14 exhibited improved selectivity for cancer cells. Apoptosis studies revealed significant cell death in MDA-MB-231 cells, with early and late apoptosis rates of 22.50% and 58.27%, respectively, alongside a marked G1-phase cell cycle arrest (49.10% in treated cells vs. 44.98% in controls). In silico toxicological evaluations indicated a favorable safety profile, with low irritancy and acceptable rat oral LD₅₀ (15.81 mg/kg) and carcinogenic potency (TD₅₀ = 36.95). Compound 14 ’s potent dual inhibition and selective cytotoxicity make it a promising candidate for further optimization and in vivo studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
- Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.
- Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
- Physics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
- Biophysics Branch, Physics Department, Faculty of Science (girls), Al-Azhar University, Nasr City, Cairo, Egypt.
- Physics Department, Faculty of Science, Al-Azhar University (Girl's Branch), Cairo, Egypt.
ORCID-Profile: Hazem Elkady, Asmaa A A Elsheshiny, Shimaa S Abdelfattah, Aisha A Alsfouk, Ahmed M Metwaly
Förderung
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
Zitieren
APA
Eissa, I. H., Elkady, H., Elgammal, W. E., Mahdy, H. A., Husein, D. Z., Amin, F. G., Elsheshiny, A. A. A., Abdelfattah, S. S., Alsfouk, A. A., Elkaeed, E. B., & Metwaly, A. M. (2025). A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy. PLOS One. https://doi.org/10.1371/journal.pone.0328305
Vancouver
Eissa IH, Elkady H, Elgammal WE, Mahdy HA, Husein DZ, Amin FG, et al. A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy. PLOS One. 2025. doi:10.1371/journal.pone.0328305
BibTeX
@article{Eissa2025,
author = {Eissa, Ibrahim H and Elkady, Hazem and Elgammal, Walid E and Mahdy, Hazem A and Husein, Dalal Z and Amin, Fatma G and Elsheshiny, Asmaa A A and Abdelfattah, Shimaa S and Alsfouk, Aisha A and Elkaeed, Eslam B and Metwaly, Ahmed M},
title = {A novel sulfamoylphenyl-dihydro-thiadiazole derivative as a dual EGFR and carbonic anhydrase inhibitor for cancer therapy},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0328305}
}
EUVIMED